Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Blatny

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Immunology Research|October 27, 2025
Atypical Phenotype of Predominant Autoimmune Cytopenia and Impaired Perforin Expression in XMEN SyndromeHana Grombirikova, Adam Markocsy, Anna Kocurkova, et al.
Scientific Reports|June 28, 2023
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicityMartin Sterba, Petra Pokorna, Renata Faberova, et al.
Journal of Thrombosis and Haemostasis : JTH|May 12, 2026
Inhibitor development according to FVIII concentrates in PUPs with severe hemophilia A: update from the PedNet registryKathelijn Fischer, Martin Olivieri, Susanna Ranta, et al.
Thrombosis and Haemostasis|January 28, 2021
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A SubjectsVictor S Blanchette, Laura Zunino, Viviane Grassmann, et al.
Journal of Thrombosis and Haemostasis : JTH|July 14, 2026
FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet RegistryMarloes de Kovel, Gili Kenet, Jayashree Motwani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2023
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centresSusanna Ranta, Jayashree Motwani, Jan Blatny, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerationsAlfonso Iorio, Andrea N Edginton, Victor Blanchette, et al.
Blood Advances|January 29, 2024
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders DatabaseSamin Mohsenian, Roberta Palla, Marzia Menegatti, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 6, 2024
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical AppraisalManuela Albisetti, Jesús Ardila, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 9, 2024
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand DiseaseMark W Skinner, Manuela Albisetti, Jesús Ardila, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Immunology Research|October 27, 2025
Atypical Phenotype of Predominant Autoimmune Cytopenia and Impaired Perforin Expression in XMEN SyndromeHana Grombirikova, Adam Markocsy, Anna Kocurkova, et al.
Scientific Reports|June 28, 2023
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicityMartin Sterba, Petra Pokorna, Renata Faberova, et al.
Journal of Thrombosis and Haemostasis : JTH|May 12, 2026
Inhibitor development according to FVIII concentrates in PUPs with severe hemophilia A: update from the PedNet registryKathelijn Fischer, Martin Olivieri, Susanna Ranta, et al.
Thrombosis and Haemostasis|January 28, 2021
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A SubjectsVictor S Blanchette, Laura Zunino, Viviane Grassmann, et al.
Journal of Thrombosis and Haemostasis : JTH|July 14, 2026
FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet RegistryMarloes de Kovel, Gili Kenet, Jayashree Motwani, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 30, 2023
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centresSusanna Ranta, Jayashree Motwani, Jan Blatny, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerationsAlfonso Iorio, Andrea N Edginton, Victor Blanchette, et al.
Blood Advances|January 29, 2024
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders DatabaseSamin Mohsenian, Roberta Palla, Marzia Menegatti, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 6, 2024
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical AppraisalManuela Albisetti, Jesús Ardila, Jan Astermark, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 9, 2024
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand DiseaseMark W Skinner, Manuela Albisetti, Jesús Ardila, et al.
Pageof 3